IDO1 and delirium: Concerning a possible molecular basis for the manifestation of delirium during CCH, our findings serve as a platform to promote future research on IDO-induced immunological tolerance for therapeutic potential targeting CCH and neurodegenerative diseases such as delirium and dementia.